Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates

AIDS Research and Human Retroviruses

Volumn 16, Issue 10, 2000, Pages 981-994

  Stamatatos, Leonidas ^a,b   Lim, Michell ^a   Cheng Mayer, Cecilia ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 140; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ARTICLE; CONFORMATIONAL TRANSITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; VIRION; VIRUS ENVELOPE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE PRODUCTS, ENV; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; IMMUNODOMINANT EPITOPES; MICE; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; PRECIPITIN TESTS; PROTEIN CONFORMATION; SOLUBILITY;

EID: 0034235058     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/08892220050058407     Document Type: Article

References (75)

1. 1. Levy JA: Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 1993;57:183-289.
2. 2. Moore JP, Cao Y, Ho DD, and Koup RA: Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 1994;68:5142-5155.
3. 3. Lewis J, Balfe P, Arnold C, et al.: Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants. J Virol 1998;72:8943-8951.
4. 4. Koup RA, Safrit JA, Cao Y, et al.: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-4655.
5. 5. Saffrit JT, Andrews CA, Zhu T, Ho DD, and Koup RA: Characterization of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion: Recognition of autologous virus sequences within a conserved immunodominant epitope. J Exp Med 1994;179:463-472.
6. 6. Matano T, Shibata R, Siemon C, et al.: Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol 1998;72:164-169.
7. 7. Ogg GS, Jin X, Bonhoeffer S, et al.: Quantitation of HIV-1 specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998;279:2103-2106.
8. 8. Ward RHR, Capon DJ, Jett CM, et al.: Prevention of HIV-1 IIIb infection in chimpanzees by CD4 immunoadhesin. Nature (London) 1991;352:434-436.
9. 9. Emini EA, Schleif WA, Nunberg JH, et al.: Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature (London) 1992;355:728-730.
10. 10. Conley AJ, Kessler JA III, Boots LN, et al.: The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J Virol 1996;70:6751-6758.
11. 11. Murthy KK, Cobb EK, Rouse, SR, et al.: Active and passive immunization against HIV type 1 infection in chimpanzees. AIDS Res Hum Retroviruses 1998;14:S-271-S-276.
12. 12. Sibata R, Igarashi T, Haigwood N, et al.: Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nature Med 1999;5:204-210.
13. 13. Igarashi T, Brown C, Azadegan A, et al.: Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nature Med 1999;5:211-216.
14. 14. Otteken A, Earl PL, and Moss B: Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates. J Virol 1996;70:3407-3415.
15. 15. Stein BS and Engleman EG: Intracellular processing of the gp160 HIV-1 envelope precursor. J Biol Chem 1990;265:2640-2649.
16. 16. Veronese FD, DeVico AL, Copeland TD, et al.: Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. Science 1985;229:1402-1405.
17. 17. Allan JS, Coligan JE, Barin F, et al.: Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 1985;228:1091-1094.
18. 18. Weiss CD, Levy JA, and White JM: Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles. J Virol 1990;64:5674-5677.
19. 19. Schawaller M, Smith CE, Skehel JJ, and Wiley DC: Studies with cross-linking reagents on the oligomeric structure of the Env-glycoprotein of HIV. Virology 1989;172:367-369.
20. 20. Pinter A, Honnen WJ, Tilley SA, et al.: Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. J Virol 1989;63:2674-2679.
21. 21. Earl PL, Moss B, and Doms RW: Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. J Virol 1991;61:2639-2641.
22. 22. Earl PL, Doms RW, and Moss B: Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci USA 1990;87:648-652.
23. 23. Willey RL, Bonifacino JS, Potts BJ, Martin MA, and Klausner RD: Biosynthesis, cleavage, and degradation of the human immunodeficiency virus type 1 envelope glycoprotein gp160. Proc Natl Acad Sci USA 1988;85:9580-9584.
24. 24. Gabuzda D, Olshevsky U, Bertani P, Haseltine WA, and Sodroski J: Identification of membrane anchorage domains of the HIV-1 gp160 envelope glycoprotein precursor. J Acquir Immune Defic Syndr 1991;4:34-40.
25. 25. Center RJ, Kemp BE, and Poumbourios P: Human immunodeficiency virus type 1 and 2 envelope glycoproteins oligomerize through conserved sequences. J Virol 1997;71:5706-5711.
26. 26. Earl PL and Moss B: Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein. AIDS Res Hum Retroviruses 1993;9:589-594.
27. 27. Thomas DJ, Wall JS, Hainfeld JF, et al.: gp160, the envelope glycoprotein of human immunodeficiency virus type 1, is a dimer of 125-kilodalton subunits stabilized through interactions between their gp41 domains. J Virol 1991;65:3797-3803.
28. 28. Matthews T, McDanal C, Greenwell T, et al.: Serological reactivity from HIV-1 vaccine recipients participating in the AIDS vaccine clinical trials network. AIDS Res Hum Retroviruses 1994;10: S55.
29. 29. Mascola JR, Snyder SW, Weislow OS, et al.: Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 1996;173:340-348.
30. 30. VanCott TC, Mascola JR, Loomis-Price LD, et al.: Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope. J Virol 1999;73:4640-4650.
31. 31. Burton DR: A vaccine for HIV type 1: The antibody perspective. Proc Natl Acad Sci USA 1997;94:10018-10023.
32. 32. Van Cott TC, Mascola JR, Kaminski RW, et al.: Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J Virol 1997;71:4319-4330.
33. 33. Van Cott TC, Veit SCD, Kayanaraman V, Earl P, and Birx DL: Characterization of a soluble, oligomeric HIV-1 gp160 protein as a potential immunogen J Immunol Methods 1995;183:103-117.
34. 34. Sugiura W, Broder CC, Moss B, and Earl PL: Characterization of conformation-dependent anti-gp120 murine monoclonal antibodies produced by immunization with monomeric and oligomeric human immunodeficiency virus type 1 envelope proteins. Virology 1999;254:257-267.
35. 35. Earl PL, Broder CC, Long D, et al.: Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol 1994;68:3015-3026.
36. 36. Broder CC, Earl PL, Long D, et al.: Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: Oligomer-specific and -sensitive monoclonal antibodies. Proc Natl Acad Sci USA 1994;91:11699-11703.
37. 37. Wyatt R, Kwong PD, Desjardins E, et al.: The antigenic structure of the HIV gp120 envelope glycoprotein. Nature (London) 1998; 393:705-711.
38. 38. Wyatt R and Sodroski J: The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 1998;280:1884-1888.
39. 39. Kwong PD, Wyatt R, Robinson J, et al.: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (London) 1998;393:648-659.
40. 40. Bou-Habib DC, Roderiquez G, Oravesz T, et al.: Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol 1994;68:6006-6013.
41. 41. Moore JP, McKeating JA, Huang Y, Askenazi A, and Ho DD: Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-senstive isolates. J Virol 1992;66:235-243.
42. 42. Stamatatos L and Cheng-Mayer C: Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding. J Virol 1995;69:6191-6198.
43. 43. Sullivan N, Sunn Y, Li J, Hofmann W, and Sodroski J: Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol 1995;69:4413-4422.
44. 44. Fouts TR, Binley JM, Trkola A, Robinson JE, and Moore JP: Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J Virol 1997;71:2779-2785.
45. 45. Fouts TR, Trkola A, Fung MS, and Moore JP: Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: Relationship to neutralization. AIDS Res Hum Retroviruses 1998;14:591-597.
46. 46. Reitter JN, Means RE, and Desrosiers RC: A role for carbohydrates in immune evasion in AIDS. Nature Med 1998;4:679-684.
47. 47. Cao J, Sullivan N, Desjardin E, et al.: Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol 1997;71:9808-9812.
48. 48. Stamatatos L and Cheng-Mayer C: An envelope modification that renders a primary, neutralization resistant, clade B HIV-1 isolate highly susceptible to neutralization by sera from other clades. J Virol 1998;72:7840-7845.
49. 49. Stamatatos L, Wiskerchen M, and Cheng-Mayer C: Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV-1 isolate on viral envelope structure, cell-entry and replication. AIDS Res Hum Retroviruses 1998;14:1129-1139.
50. 50. Earl PL, Broder CC, Doms RW, and Moos B: Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J Virol 1997;71:2674-2684.
51. 51. Gorny MK, Xu J-Y, Karwowska S, Buchbinder A, and Zolla-Pazner S: Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol 1993; 150:635-643.
52. 52. Seligman SJ, Binley JM, Gorny MK, et al.: Characterization by serial competition ELISAS of HIV-1 V3 loop epitopes recognized by monoclonal antibodies. Mol Immunol 1996;33:737-745.
53. 53. Thali M, Moore JP, Furma C, et al.: Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 1993;67: 3978-3988.
54. 54. Burton DR, Pyati J, Koduri R, et al.: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994;266:1024-1027.
55. 55. Roben P, Moore JP, Thali M, et al.: Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994;68:4821-4828.
56. 56. Sullivan N, Thali M, Furman C, Ho DD, and Sodroski J: Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. J Virol 1993;67:3674-3679.
57. 57. Fung MSC, Sun CRY, Gordon WL, et al.: Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1. J Virol 1992;66: 848-856.
58. 58. Cheng-Mayer C, Liu R, Landau NR, and Stamatatos L: Macrophage tropism of HIV-1 and utilization of the CC-CKR5 coreceptor. J Virol 1997;71:1657-1661.
59. 59. Stamatatos L and Cheng-Mayer C: Evidence that the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity, host range, and syncytium-forming ability. J Virol 1993;67:5635-5639.
60. 60. Stamatatos L, Werner A, and Cheng-Mayer C: Differential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1. J Virol 1994;68:4973-4979.
61. 61. Stamatatos L, Zolla-Pazner S, Gorny M, and Cheng-Mayer C: Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: Effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells. Virology 1997;229:360-369.
62. 62. Richardson JTM, Stryjewski BL, Broder CC, et al.: Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J Virol 1996;70:753-762.
63. 63. Ditzel HJ, Binley JM, Moore JP, et al.: Neutralizing recombinant human antibodies to a conformational V2-and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure. J Immunol 1995;154:893-906.
64. 64. Mo H, Stamatatos L, Ip JE, et al.: Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. J Virol 1997;71:6869-6874.
65. 65. Parren PWHI, Fisicaro P, Labrijn AF, et al.: In vitro antigen challenge of human antibody libraries for vaccine evaluation: The human immunodeficiency virus type 1 envelope. J Virol 1996;70: 9046-9050.
66. 66. Sattentau QJ and Moore JP: Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med 1991;174:407-415.
67. 67. Sattentau QJ, Moore JP, Vignaux F, Traincard F, and Poignard P: Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. J Virol 1993;67:7383-7393.
68. 68. Stamatos NM, Mascola JR, Kalyanaraman VS, et al.: Neutralizing antibodies from sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140. J Virol 1998;72:9656-9667.
69. 69. Farzan M, Choe H, Desjardins E, et al.: Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain. J Virol 1998;72:7620-7625.
70. 70. McCune JM, Rabin LB, Feinferg MB, et al.: Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell 1988;53:55-67.
71. 71. Freed EO, Myers DJ, and Risser R: Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope glycoprotein precursor gp160. J Virol 1989;63:4670-4675.
72. 72. Kowalski M, Potz J, Basiripour L, et al.: Functional regions of the human immunodeficiency virus envelope glycoprotein. Science 1987;237:1351-1355.
73. 73. Berman PW, Nuñes WM, and Haffar OK: Expression of membrane-associated and secreted variants of gp160 of human immunodeficiency virus type 1 in vitro and in continuous cell lines. J Virol 1988;62:3135-3142.
74. 74. Trkola A, Dragic T, Arthos J, et al.: CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR5. Nature (London) 1996;384:184-187.
75. 75. Wu L, Gerard NP, Wyatt R, et al.: CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR5. Nature (London) 1996;384:179-183.